2,4,6-trimorpholino-1,3,5-triazine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 85361 |
| CHEMBL ID | 189616 |
| SCHEMBL ID | 8973821 |
| MeSH ID | M0529182 |
| Synonym |
|---|
| smr000280843 |
| MLS000711076 |
| CHEMDIV1_000300 |
| OPREA1_275678 |
| OPREA1_034407 |
| nsc-80863 |
| nsc80863 |
| 16303-23-4 |
| STK046157 |
| 2,4,6-tri(morpholin-4-yl)-1,3,5-triazine |
| CHEMBL189616 |
| AKOS000678064 |
| HMS587N14 |
| ghkbocaecrmabj-uhfffaoysa- |
| inchi=1/c15h24n6o3/c1-7-22-8-2-19(1)13-16-14(20-3-9-23-10-4-20)18-15(17-13)21-5-11-24-12-6-21/h1-12h2 |
| 4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)morpholine |
| NCGC00245500-01 |
| unii-62be4yp783 |
| 62be4yp783 , |
| ai3-51241 |
| 1,3,5-triazine, 2,4,6-tri-4-morpholinyl- |
| 2,4,6-tris(morpholino)-1,3,5-triazine |
| einecs 240-391-7 |
| nsc 80863 |
| HMS2749J20 |
| AB00073567-01 |
| SCHEMBL8973821 |
| DTXSID60167502 |
| tris(morpholin-4-yl)-1,3,5-triazine |
| sr-01000396401 |
| SR-01000396401-1 |
| 2,4,6-trimorpholino-1,3,5-triazine |
| EN300-18303318 |
| 2,4,6-tri-4-morpholinyl-1,3,5-triazine |
| s-triazine, 2,4,6-trimorpholino- |
| Z57705663 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 3.9811 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| TDP1 protein | Homo sapiens (human) | Potency | 18.3564 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 79.4328 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 89.1251 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 11.2202 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| negative regulation of inflammatory response to antigenic stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| renal water homeostasis | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| G protein-coupled receptor signaling pathway | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| regulation of insulin secretion | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| cellular response to glucagon stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| G protein activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| adenylate cyclase activator activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID248022 | Cytotoxic activity of compound towards human L1210 cell line after 72 hr of administration | 2004 | Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19 | In vitro cytotoxic activities of 2-alkyl-4,6-diheteroalkyl-1,3,5-triazines: new molecules in anticancer research. |
| AID248005 | Cytotoxic activity of compound towards human HL60 cell line after 72 hr of administration | 2004 | Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19 | In vitro cytotoxic activities of 2-alkyl-4,6-diheteroalkyl-1,3,5-triazines: new molecules in anticancer research. |
| AID248004 | Cytotoxic activity of compound towards human HL60 cell line after 48 hr of administration | 2004 | Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19 | In vitro cytotoxic activities of 2-alkyl-4,6-diheteroalkyl-1,3,5-triazines: new molecules in anticancer research. |
| AID293207 | Growth inhibition of human HCT116 cells at 10 uM after 72 hrs by SRB assay | 2007 | Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4 | Synthesis and antitumor evaluation of a novel series of triaminotriazine derivatives. |
| AID248193 | Cytotoxic activity of compound towards human leukemia L1210 cell line after 48 hr of administration | 2004 | Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19 | In vitro cytotoxic activities of 2-alkyl-4,6-diheteroalkyl-1,3,5-triazines: new molecules in anticancer research. |
| AID248107 | Cytotoxic activity of compound towards human glioma C6 cell line after 72 hr of administration | 2004 | Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19 | In vitro cytotoxic activities of 2-alkyl-4,6-diheteroalkyl-1,3,5-triazines: new molecules in anticancer research. |
| AID248106 | Cytotoxic activity of compound towards human glioma C6 cell line after 48 hr of administration | 2004 | Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19 | In vitro cytotoxic activities of 2-alkyl-4,6-diheteroalkyl-1,3,5-triazines: new molecules in anticancer research. |
| AID293206 | Growth inhibition of human HT29 cells at 10 uM after 72 hrs by SRB assay | 2007 | Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4 | Synthesis and antitumor evaluation of a novel series of triaminotriazine derivatives. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||